Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis.
Angiotensin-converting enzyme (ACE) inhibitors are frequently used to treat hypertension in children.(1) ACE inhibitors alter the balance between the vasoconstrictive, salt-retentive, and cardiac hypertrophic properties of angiotensin II and the vasodilatory and natriuretic properties of bradykinin; they also alter the metabolism of other vasoactive substances.(2) Through these mechanisms, ACE inhibitors decrease systemic vascular resistance and promote natriuresis without increasing heart rate. This study evaluated the results of six trials of ACE inhibitors in children, using meta-analytic techniques to estimate the effect of race on blood pressure response.
Office of Pediatric Therapeutics, Office of the Commissioner, US Food and Drug Administration, Rockville, Maryland, USA. jennifer.li@duke.edu
J S
JS
Li
C M
CM
Baker-Smith
P B
PB
Smith
V
V
Hasselblad
M D
MD
Murphy
R M
RM
Califf
D K
DK
Benjamin
D000293:Adolescent; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D044383:Black People; D001794:Blood Pressure / Q000187:drug effects*; D002648:Child; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D016032:Randomized Controlled Trials as Topic; D044465:White People
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents